雷珠单抗治疗-延长方案治疗新生血管性年龄相关性黄斑变性的24个月随机临床试验
CANTREAT试验在加拿大27个中心纳入580例未治疗的新生血管性AMD患者,随机比较雷珠单抗治疗-延长(T&E)方案与每月给药方案。24个月时T&E组平均注射17.6次、每月组23.5次,两组BCVA平均改善分别为6.8和6.0个字母,T&E不劣于每月给药,且注射和随访次数更少。
要点
- T&E方案24个月视力改善不劣于每月给药,平均差0.9个字母(95%CI -1.6至3.3)。
- T&E组两年平均注射17.6次,每月组23.5次,减少约5.9次注射和随访。
- 两组视力增益≥15字母和丢失≥15字母的比例差异均无统计学意义。
核心结论
- 新生血管性AMD患者采用雷珠单抗T&E方案至24个月,视力变化不劣于每月给药方案,且注射和随访次数更少。
研究设计与样本
- 随机、开放标签、多中心、非劣效性意向治疗试验,在加拿大27个治疗中心开展。
- 纳入580例未治疗的新生血管性AMD继发脉络膜新生血管患者,1:1随机接受雷珠单抗0.5 mg T&E或每月给药。
- 主要终点为基线至第24个月BCVA(ETDRS字母)平均变化,12个月非劣效界值为-5个字母。
主要发现
- 24个月时T&E组平均注射17.6次,每月组23.5次,差异5.9次(95%CI 5.4-6.5;P < .001)。
- BCVA平均改善T&E组6.8个字母,每月组6.0个字母,差异0.9个字母(95%CI -1.6至3.3;P = .21)。
- 视力增益≥15字母比例T&E组25.5%、每月组23.1%(差异2.4%;95%CI -6.8%至11.6%;P = .59)。
- 视力丢失≥15字母比例T&E组6.5%、每月组5.8%(差异-0.7%;95%CI -9.9%至8.5%;P = .85)。
关键数值与推荐
- 非劣效界值为12个月BCVA较基线变化组间差异-5个字母。
- 24个月T&E组平均注射17.6次,每月组23.5次,差异5.9次(95%CI 5.4-6.5;P < .001)。
- 24个月BCVA平均改善T&E组6.8个字母,每月组6.0个字母,差异0.9个字母(95%CI -1.6至3.3;P = .21)。
临床怎么用
- 对新生血管性AMD患者,雷珠单抗可采用T&E方案以减少注射和随访负担,同时维持与每月给药相当的视力获益。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Although the Canadian Treat-and-Extend Analysis Trial With Ranibizumab in Patients With Neovascular Age-Related Macular Disease (CANTREAT) reported herein and the Treat and Extend study provided data to show noninferiority of treat-and-extend (T&E) at 12 months, to date there are few data on 24-month T&E trials compared with monthly dosing. OBJECTIVE: To compare the efficacy of ranibizumab using a T&E regimen to monthly dosing in treatment-naive patients with neovascular age-related macular degeneration (nAMD) after 24 months. DESIGN, SETTING, AND PARTICIPANTS: A randomized, open-label, multicenter, noninferiority intention-to-treat trial with a margin of -5 letters in best-corrected visual acuity (BCVA) from baseline to 12 months between groups was conducted at 27 treatment centers in Canada. Participants included 580 patients with treatment-naive choroidal neovascularization secondary to AMD. The study was conducted from May 8, 2013, to August 28, 2018, and data analysis was performed between August 29 and September 12, 2018. INTERVENTIONS: Patients with nAMD were randomized 1:1 to receive intravitreal ranibizumab, 0.5 mg, in either a T&E or monthly dosing regimen. MAIN OUTCOMES AND MEASURES: Mean change in BCVA in Early Treatment of Diabetic Retinopathy Study letters from baseline to month 24. RESULTS: Of the 580 randomized patients, 350 were women (60.3%) and 547 were white (94.3%). Mean (SD) age was 78.8 (7.8) years. By the end of month 24, 466 of the 580 randomized patients (80.3%) had completed the study and participants in the T&E arm received a mean of 17.6 injections compared with 23.5 injections for the monthly arm, for a difference of 5.9 injections and visits over 2 years (95% CI, 5.4-6.5; P < .001). The mean (SD) BCVA improvement was not worse with the T&E arm, 6.8 (14.1) letters vs 6.0 (12.6) letters, compared with the monthly arm (difference, 0.9; 95% CI, -1.6 to 3.3; P = .21). There was a gain of 15 or more letters in 25.5% of the T&E group and 23.1% of the monthly treatment group (difference, 2.4%; 95% CI, -6.8% to 11.6%; P = .59) and a loss of 15 or more letters in 6.5% of the T&E group and 5.8% of the monthly treatment group (difference, -0.7%; 95% CI, -9.9% to 8.5%; P = .85). CONCLUSIONS AND RELEVANCE: These findings suggest that change in vision from baseline is not worse with a T&E compared with a monthly regimen of ranibizumab for nAMD through 24 months, achieving clinically meaningful improvements in BCVA despite fewer injections and visits. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02103738.
引用
- Kertes PJ, Galic IJ, Greve M, et al. Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease: A Randomized Clinical Trial. JAMA Ophthalmol. 2020. PMID: 31917441. doi:10.1001/jamaophthalmol.2019.5540
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。